A
Attovia Therapeutics
ATTORecent IPOAttovia Therapeutics, Inc. · Nasdaq · Immune-disease biotechnology · Report filing 2026/08/05 · SEC checked 2026-10-07
DAILY SEC UPDATE424B4 analysed from the latest filing
Attovia priced its IPO at $17.00 per share for 17.0 million shares, with Nasdaq listing approved under ATTO.
One-minute decisionBASIC RESEARCHSource completeness · 84%
Newly listed — review valuation, deal quality and post-IPO supply before acting
Attovia Therapeutics, Inc. began trading on 2026-08-05 at an IPO price of $17.00; the final prospectus and offer terms are linked to SEC EDGAR.
Capital destination
—No estimate is substituted for missing offer terms.
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · 424B4 ↗Capital destination
—No estimate is substituted for missing offer terms.
Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.
Check the source · 424B4 ↗BOOKRUNNERS / LEAD UNDERWRITERSUnderwriting syndicate
CONFIRMED- 1Morgan Stanley & Co. LLC40.00%6,800,000 shares
- 2Leerink Partners LLC28.00%4,760,000 shares
- 3Citigroup Global Markets Inc.19.00%3,230,000 shares
View all 5 institutions ＋
- 4RBC Capital Markets, LLC7.00%1,190,000 shares
- 5LifeSci Capital LLC6.00%1,020,000 shares
Fully diluted valuation bridge
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Basic-price scenario
A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.
Check the source · 424B4 ↗Existing holders
~60.5%*The estimate compares offered shares with the latest reported shares outstanding and is not a voting-control conclusion.
Latest available filing · 2026/08/05
Review the beneficial-ownership table and voting rights together
One disclosed holder; not a complete ownership distribution.Check the source · 424B4 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
Calendar dates from 2026-08-05
- First trading day17.000M IPO shares
| Holder / event | Term / date | Conditions |
|---|---|---|
| First trading day | 2026-08-05 ~39.5%* · 17.000M IPO shares | 17.000M IPO shares |
Basis and evidence
First trading day
First trading day · 17.000M IPO shares
Lock-up / shares eligible for future sale ↗Financial quality and runway
| Status | Reference |
|---|---|
| Awaiting verification | Source ↗ |
Latest filing update
Loading saved filing update…
Clinical development, regulatory approval and cash-runway outcomes can change the equity value materially.
- Potential impact
- High
- Monitor
- First post-IPO filing and lock-up schedule
- Evidence
- 424B4 · 2026/08/05 ↗
Document424B4✓ Verified against the SEC source · SEC source document
Filed2026/08/051 public filings identified
Research updated2026/08/05SEC EDGAR
Evidence coverage84%Final prospectus, offer price, listing date and headline financial evidence reconciled
What remains missing16% of the evidence set remains unresolved. This may affect unconfirmed pricing, valuation, dilution or supply conclusions; no missing term is estimated.
View the filing's actual first page ＋
